Very early molecular responses in the first two months of therapy are highly predictive of deep molecular responses at 18 months, in chronic myeloid leukemia patients treated upfront with nilotinib
Servicios
Servicios
Fecha de publicación
2014Título de revista
Haematologica
Tipo de contenido
Publicación de congreso
